News – Page 1002 – Endpoints News

6 months after arriving at Sanofi R&D, John Reed gambles $125M on Denali’s RIPK1 work

7 years ago

Tonix jumps on rejigged phase III for PTSD drug; MeiraGTx scores another NIH deal; OpGen, Qiagen join hands to detect ...

7 years ago

FDA staff suggests safety profile of Sage postpartum depression drug disqualifies it from at-home infusions

7 years ago

Weeks after launching Aeterna Zentaris castoff, Strongbridge turns around and sells rights to Novo Nordisk — at a ...

7 years ago

Gilead throws its weight — and $50M cash — behind Tango's I/O discovery engine

7 years ago

GSK tosses a trio of clinical-stage drugs on trial failures, winnowing out its respiratory pipeline as cancer moves ...

7 years ago

Acadia says Nuplazid cleared main goal in depression study, but data appear mixed

7 years ago

Gene therapy developer Orchard prices IPO at $14 to raise $200M

7 years ago

Finally! Innovent hikes on Hong Kong debut amid cloudy market sentiments

7 years ago

Feds charge a group of Genentech vets with another scheme to steal trade secrets — this time to help a Taiwanese ...

7 years ago

The next big thing at GlaxoSmithKline R&D is clearly oncology — respiratory can take a back seat now

7 years ago

Roche adds $25M to Halozyme pact for fresh targets; FDA OKs cardio indication for J&J's Invokana

7 years ago

WuXi dives into computational drug discovery, launches New York-based JV with Schrödinger

7 years ago

Arch Venture sets its sights on raising $600M for Fund X

7 years ago

Problems, problems, problems: But Alkermes will fight it out this week over the FDA’s objections to its big ...

7 years ago

Terns scores $80M in Series B financing led by Vivo, OrbiMed

7 years ago

Novartis has scrapped a fifth of its programs in pursuit of 'truly impactful' drugs, Bradner reveals

7 years ago

AstraZeneca hands over some rights to Nexium, Vimovo to Grünenthal as it plots turnaround

7 years ago

Out to challenge Gilead's daily pills, Viiv scores three-year data on monthly combo; Rigel bags $33M from Asia ...

7 years ago

Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab

7 years ago

TherapeuticsMD wins FDA nod for hormone therapy, capping off drugmaker's prolific year

7 years ago

Pfizer, Novartis tie up to target NASH in crowded field

7 years ago

A photo log of my week in Shanghai, hosting the first annual US-China Biopharma Innovation and Investment Summit

7 years ago

On a roll, Dicerna notches $100M upfront as Eli Lilly eyes RNAi applications in neurodegeneration, pain

7 years ago

First page Previous page 999 1000 100110021003 1004 1005 Next page Last page